← Back to All US Stocks

BHST Stock Analysis - BIOHARVEST SCIENCES INC. AI Rating

BHST Nasdaq Pharmaceutical Preparations A1 CIK: 0001723464
Recently Updated • Analysis: Mar 21, 2026 • SEC Data: 2026-03-21
AI Rating
SELL
95% Confidence

📊 BHST Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: SELL with 95% confidence

Investment Thesis

BioHarvest Sciences presents substantial analytical risk due to complete absence of reportable financial data across all fundamental metrics. With zero revenue, no profitability indicators, no balance sheet data, and only 1 metric available from SEC filings, the company appears to be pre-revenue or non-operational. The lack of insider activity (0 Form 4 filings in 90 days) combined with missing financial data suggests minimal operational progress.

BHST Strengths

  • + Listed on Nasdaq indicating regulatory compliance standards
  • + CIK registration demonstrates SEC reporting entity status
  • + Operating in pharmaceutical sector with potential long-term market opportunity

BHST Risks

  • ! Complete absence of revenue and profitability metrics
  • ! No balance sheet data available indicating non-reporting status or financial distress
  • ! Zero insider transactions in 90 days suggests lack of management confidence
  • ! Pharmaceutical sector carries high R&D costs and regulatory risk
  • ! Insufficient financial transparency for fundamental analysis

Key Metrics to Watch

BHST Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

BHST Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

BHST vs Healthcare Sector

How BIOHARVEST SCIENCES INC. compares to Healthcare sector averages

Net Margin
BHST 0.0%
vs
Sector Avg 12.0%
BHST Sector
ROE
BHST 0.0%
vs
Sector Avg 15.0%
BHST Sector
Current Ratio
BHST 0.0x
vs
Sector Avg 2.0x
BHST Sector
Debt/Equity
BHST 0.0x
vs
Sector Avg 0.6x
BHST Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

BHST Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

BHST Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

BHST SEC Filings

Access official SEC EDGAR filings for BIOHARVEST SCIENCES INC. (CIK: 0001723464)

Frequently Asked Questions about BHST

What is the AI rating for BHST?

BIOHARVEST SCIENCES INC. (BHST) has an AI rating of SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are BHST's key strengths?

Listed on Nasdaq indicating regulatory compliance standards. CIK registration demonstrates SEC reporting entity status.

What are the risks of investing in BHST?

Complete absence of revenue and profitability metrics. No balance sheet data available indicating non-reporting status or financial distress.

What is BHST's revenue and growth?

BIOHARVEST SCIENCES INC. reported revenue of N/A.

Does BHST pay dividends?

BIOHARVEST SCIENCES INC. does not currently pay dividends.

Where can I find BHST SEC filings?

Official SEC filings for BIOHARVEST SCIENCES INC. (CIK: 0001723464) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is BHST's EPS?

BIOHARVEST SCIENCES INC. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 21, 2026 | Data as of: 2026-03-21 | Powered by Claude AI